Teleflex to close Minnesota facility, cut 101 employees
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter.
Teleflex will close a manufacturing facility in Maple Grove, Minnesota, by next March and cut more than 100 employees as a result.
The planned closure will affect an expected 101 positions, according to a Tuesday Worker Adjustment and Retraining Notification filing obtained by MedTech Dive. The Minnesota Star Tribune first reported the cuts.
Most laboratory and manufacturing operations are expected to cease by June 30, with the layoffs occurring on July 1, according to the filing. Teleflex did not respond to a request for comment on why it was closing the Maple Grove facility.
In February, Teleflex announced it would split into two separate, public entities. A new company would comprise Teleflex's urology, acute care and OEM businesses, while the remaining company would include the vascular access, interventional and surgical businesses. Simultaneously, Teleflex bought Biotronik's vascular intervention division.
Teleflex aims to streamline manufacturing during the restructuring. The company aims to reduce the number of facilities from the combination of Biotronik and the remaining company from 19 facilities to seven, CEO Liam Kelly told investors in February.
The Maple Grove site was used to make diagnostic and interventional catheters, according to the company's website. Teleflex's remaining company had pro forma revenue of $2.1 billion in 2024 with the Biotronik acquisition.
Recommended Reading
Teleflex to split in 2, buy Biotronik assets for $791M among slew of actions
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Owens & Minor spikes $1.36B Rotech buyout over regulatory barriers
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Owens & Minor said Thursday it has terminated the planned $1.36 billion acquisition of home medical equipment company Rotech Healthcare Holdings. The companies mutually agreed to terminate the deal after getting regulatory clearance 'proved unviable in terms of time, expense and opportunity,' Owens & Minor CEO Edward Pesicka said in a statement. Owens & Minor originally aimed to close the takeover by the end of last year. However, the deal was held up by the Federal Trade Commission's review. Owens & Minor and Rotech announced the acquisition in July 2024. Having set the goal of almost doubling patient direct sales by 2028, Owens & Minor moved to boost its position in areas including respiratory and sleep apnea products by acquiring Rotech. Privately owned Rotech reported $750 million in net revenue in 2023. The closing date was delayed by an FTC investigation. Owens & Minor and Rotech entered into a timing agreement with the FTC that gave the federal agency until June 10 to complete its review of the deal. Days from the deadline, Owens & Minor and Rotech terminated the takeover agreement. Pesicka said the merger would have provided 'ample benefits to patients, payors, and providers.' Yet, the 'path to obtain regulatory clearance' proved unviable, the CEO said, driving the companies to drop the merger. Owens & Minor paid Rotech $80 million in conjunction with the termination. The company previously said the deal included a $70 million termination fee. The $80 million termination payment brings Owens & Minor's spending on the deal above $100 million. Acquisition-related costs totaled $22 million in 2024 and $16 million in the first quarter of 2025. The termination closed off an avenue to Owens & Minor's 2028 patient direct sales target but investors reacted positively to the news. Shares in Owens & Minor jumped 14% to close at $7.61 on Thursday. Rotech's revenue fell almost 4% to $725.8 million last year. Asked about the results on an earnings call with analysts last month, Owens & Minor CFO Jonathan Leon said the declines 'were largely anticipated and largely resulted from a lot of COVID-era benefit that the industry got to realize that fell off in early 2024.' Recommended Reading Owens & Minor inks $1.36B takeover of Rotech
Yahoo
a day ago
- Yahoo
EU plan would limit Chinese device makers in Europe
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. European Union member states this week voted to support a plan to adopt measures that would restrict Chinese medical device makers' access to the EU market. The member states took the action, under the EU's International Procurement Instrument, after concluding an investigation in January that looked at China's practices in the public procurement market for medical devices. The investigation found that government practices unfairly encouraged Chinese hospitals to choose domestic manufacturers' products. 'The Commission has identified measures and practices in the Chinese procurement market that lead to discrimination against EU operators and EU-made supplies,' Olof Gill, commission spokesperson, said Thursday in an emailed statement. 'This discrimination also harms both the Chinese healthcare infrastructure, which is deprived of quality equipment, and EU businesses, with a high cost in terms of jobs and economic activity in the EU.' The commission has discussed its concerns with Chinese authorities. However, a satisfactory solution has not been proposed, and the EU had no other option than to tackle the issue through an IPI investigation, Gill wrote. The commission said it could not disclose the content of the draft IPI measure or next steps in the process. Chinese manufacturers would be prohibited from bidding on public procurement contracts worth more than 5 million euros for five years. In addition, no more than 50% of a contract's value may be subcontracted to Chinese entities or include Chinese-origin medical devices, MedTech Europe said in a statement. The trade group said it would provide further updates once the IPI measures are published in the EU's official journal. The EU investigation into China's medical device procurement practices was the first use of the IPI, which was introduced in 2022. Getting fair access to Chinese markets became more challenging for medical device companies after the country launched a program calling for domestically produced medical equipment to achieve 50% market penetration in county-level hospitals by 2020 and 70% by 2025, according to a statement from the European Chamber, which represents European businesses in China. European and Chinese leaders will meet in July at a summit in Beijing. Recommended Reading EU mulls retaliation after showing China's bias against foreign device firms Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 days ago
- Yahoo
Neuralink raises $650M to help expand patient access
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Elon Musk's Neuralink closed a $650 million funding in a Series E round, the company said Monday. The company said it plans to use the funds to expand patient access and 'innovate future devices that deepen the connection between biological and artificial intelligence.' Neuralink also announced that its brain implant has entered clinical trials in three countries, and that five people with severe paralysis are now using the implant to control digital and physical devices. Neuralink's brain computer interface consists of a chip that is surgically implanted in the skull, as well as electrodes that connect to the brain's cerebral cortex. It's designed to allow people to control a computer or mobile device. The latest fundraise included investors ARK Invest, Founders Fund, G42, Lightspeed, Sequoia Capital and others. Neuralink previously raised $280 million in a Series D round in 2023. Last year, Noland Arbaugh became the first person to receive the implant, which allowed him to move a cursor on a screen and play video games. Since then, Neuralink has sought additional applications. The company said last month it received the Food and Drug Administration's breakthrough designation to help restore communication for individuals with severe speech impairment. In Monday's announcement, Neuralink also said it had received breakthrough designation for vision restoration programs. The FDA determines breakthrough devices based on their potential for more effective treatment of life-threatening or irreversibly debilitating conditions. The designation gives manufacturers the opportunity to meet with FDA experts and have their submissions prioritized for review. Neuralink also said it has started clinical trials at the Barrow Neurological Institute in Phoenix, The Miami Project to Cure Paralysis at the University of Miami, the Cleveland Clinic Abu Dhabi and the University Health Network in Toronto. Recommended Reading Elon Musk's brain implant company raises $280M to fund clinical trials Melden Sie sich an, um Ihr Portfolio aufzurufen.
